Expression and activity of soluble guanylate cyclase in injury and repair of anti-thy1 glomerulonephritis

Kidney International

Volumn 66, Issue 6, 2004, Pages 2224-2236

  Peters, Harm ^a   Wang, Yingrui ^a   Loof, Tanja ^a   Martini, Sebastian ^a   Kron, Susanne ^a   Krämer, Stephanie ^a   Neumayer, Hans H ^a  

^a HUMBOLDT UNIVERSITY   (Germany)

Author keywords

Bay 41 2272; cGMP; Fibrosis; Nitric oxide; Soluble guanylate cyclase; TGF 1

Indexed keywords

CYCLIC GMP; ENDOTHELIAL NITRIC OXIDE SYNTHASE; FIBRINOGEN; FIBRONECTIN; GUANYLATE CYCLASE; NITRIC OXIDE; PLASMINOGEN ACTIVATOR INHIBITOR 1; THY 1 ANTIGEN; TRANSFORMING GROWTH FACTOR BETA1; 3 (4 AMINO 5 CYCLOPROPYLPYRIMIDINE 2 YL) 1 (2 FLUOROBENZYL) 1H PYRAZOLO(3,4 B)PYRIDINE; 3-(4-AMINO-5-CYCLOPROPYLPYRIMIDINE-2-YL)-1-(2-FLUOROBENZYL)-1H-PYRAZOLO(3,4-B)PYRIDINE; ALLOANTIBODY; ANTI THY ANTIBODY; ANTI-THY ANTIBODY; CELL RECEPTOR; MESSENGER RNA; NITRIC OXIDE SYNTHASE; NOS3 PROTEIN, RAT; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE; SOLUBLE GUANYLYL CYCLASE; TGFB1 PROTEIN, RAT; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLEEDING TIME; CELL INFILTRATION; CONTROLLED STUDY; ENZYME ACTIVITY; GLOMERULONEPHRITIS; MACROPHAGE; MESANGIUM CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEINURIA; RAT; SCORING SYSTEM; STATISTICAL SIGNIFICANCE; SYNTHESIS; THROMBOCYTE; ANIMAL; BLOOD; BLOOD PRESSURE; BODY WEIGHT; GENETICS; GLOMERULUS; IMMUNOLOGY; IN VITRO STUDY; MALE; METABOLISM; PATHOLOGY; WISTAR RAT;

ANIMALS; BLEEDING TIME; BLOOD PRESSURE; BODY WEIGHT; CYCLIC GMP; GLOMERULONEPHRITIS; GUANYLATE CYCLASE; ISOANTIBODIES; KIDNEY GLOMERULUS; MACROPHAGES; MALE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE III; PYRAZOLES; PYRIDINES; RATS; RATS, WISTAR; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RNA, MESSENGER; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1;

EID: 21644445065     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1523-1755.2004.66012.x     Document Type: Article

References (36)

1. MONCADA S: Nitric oxide in the vasculature: physiology and pathophysiology. Ann NY Acad Sci 811:60-67, 1997
2. MCDONALD LJ, MURAD F: Nitric oxide and cyclic GMP signaling. Proc Soc Exp Biol Med 211:1-6, 1996
3. MAYER B, KOESLING D: cGMP signalling beyond nitric oxide. Trends Pharmacol Sci 22:546-548, 2001
4. THEILIG F, BOSTANJOGLO M, PAVENSTADT H, et al: Cellular distribution and function of soluble guanylyl cyclase in rat kidney and liver. J Am Soc Nephrol 12:2209-2220, 2001
5. RUTH P: Cyclic GMP-dependent protein kinases: Understanding in vivo functions by gene targeting. Pharmacol Ther 82:355-372, 1999
6. REYES AA, KARL IE, KLAHR S: Role of arginine in health and in renal disease. Am J Physiol 267:F331-F346, 1994
7. KONE BC: Nitric oxide in renal health and disease. Am J Kidney Dis 30:311-333, 1997
8. NORIS M, REMUZZI G: Physiology and pathophysiology of nitric oxide in chronic renal disease. Proc Assoc Am Physicians 111:602-610, 1999
9. SCHMIDT RJ, BAYLIS C: Total nitric oxide production is low in patients with chronic renal disease. Kidney Int 58:1261-1266, 2000
10. PETERS H, BORDER WA, NOBLE NA: From rats to men: A perspective on dietary L-arginine supplementation in human renal disease. Nephrol Dial Transplant 14:1640-1650, 1999
11. PETERS H, BORDER WA, NOBLE NA: Tandem antifibrotic actions of L-arginine supplementation and low protein diet during the repair phase of experimental glomerulonephritis. Kidney Int 57:922-1001, 2000
12. PETERS H, DAIG U, MARTINI S, et al: NO mediates antifibrotic actions of L-arginine supplementation following induction of anti-thy1 glomerulonephritis. Kidney Int 64:509-518, 2003
13. NARITA I, BORDER WA, KETTELER M, NOBLE NA: Nitric oxide mediates immunologic injury to kidney mesangium in experimental glomerulonephritis. Lab Invest 72:17-24, 1995
14. STASCH JP, BECKER EM, ALONSO-ALIJA C, et al: NO-independent regulatory site on soluble guanylate cyclase. Nature 410:212-215, 2001
15. PETERS H, EISENBERG R, DAIG U, et al: Platelet inhibition limits TGF-β overexpression and matrix expansion following induction of anti-thy1 glomerulonephritis. Kidney Int 65:2238-2248, 2004
16. PETERS H, BORDER WA, NOBLE NA: L-arginine supplementation increases mesangial cell injury and subsequent tissue fibrosis in experimental glomerulonephritis. Kidney Int 55:2264-2273, 1999
17. AHLUWALIA A, FOSTER P, SCOTLAND RS, et al: Antiinflammatory activity of soluble guanylate cyclase: cGMP-dependent downregulation of P-selectin expression and leukocyte recruitment. Proc Natl Acad Sci USA 101:1386-1391, 2004
18. GREEN LC, WAGNER DA, GLOGOWSKI J, et al: Analysis of nitrate, nitrite and 15N-nitrate in biological fluids. Anal Biochem 126:131-138, 1982
19. PFAFFL MW: A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 29:e45, 2001
20. WALKER NJ: Real-time and quantitative PCR: applications to mechanism-based toxicology. J Biochem Mol Toxicol 15:121-127, 2001
21. BACHMANN S, MUNDEL P: Nitric oxide in the kidney: Synthesis, localization, and function. Am J Kidney Dis 24:112-129, 1994
22. LEWKO B, STEPINSKI J: Cyclic GMP signaling in podocytes. Microsc Res Tech 57:232-235, 2002
23. LANDMESSER U, DIKALOV S, PRICE SR, et al: Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension. J Clin Invest 111:1201-1209, 2003
24. KAGOTA S, TAMASHIRO A, YAMAGUCHI Y, et al: Downregulation of vascular soluble guanylate cyclase induced by high salt intake in spontaneously hypertensive rats. Br J Pharmacol 134:737-744, 2001
25. RUETTEN H, ZABEL U, LINZ W, SCHMIDT HH: Downregulation of soluble guanylyl cyclase in young and aging spontaneously hypertensive rats. Circ Res 85:534-541, 1999
26. BAUERSACHS J, BOULOUMIE A, FRACCAROLLO D, et al: Endothelial dysfunction in chronic myocardial infarction despite increased vascular endothelial nitric oxide synthase and soluble guanylate cyclase expression: role of enhanced vascular superoxide production. Circulation 100:292-298, 1999
27. MOLLNAU H, WENDT M, SZOCS K, et al: Effects of angiotensin II infusion on the expression and function of NAD(P)H oxidase and components of nitric oxide/cGMP signaling. Circ Res 90:e58-e65, 2002
28. MARQUES M, MILLAS I, JIMENEZ A, et al: Alteration of the soluble guanylate cyclase system in the vascular wall of lead-induced hypertension in rats. J Am Soc Nephrol 12:2594-2600, 2001
29. WITTE K, JACKE K, STAHRENBERG R, et al: Dysfunction of soluble guanylyl cyclase in aorta and kidney of Goto-Kakizaki rats: Influence of age and diabetic state. Nitric Oxide 6:85-95, 2002
30. PETERS H, BORDER WA, RÜCKERT M, et al: l-Arginine supplementation accelerates renal fibrosis and shortens life span in experimental lupus nephritis. Kidney Int 63:1382-1392, 2003
31. PETERS H, RÜCKERT M, GAEDEKE J, et al: Angiotensin-converting enzyme inhibition but not beta-adrenergic blockade limits transforming growth factor-beta overexpression in acute normotensive anti-thy1 glomerulonephritis. J Hypertens 21:771-780, 2003
32. WENZEL UO, WOLF G, THAISS F, et al: Renovascular hypertension does not influence repair of glomerular lesions induced by anti-thymocyte glomerulonephritis. Kidney Int 58:1135-1147, 2000
33. WANG S, WU X, LINCOLN TM, MURPHY-ULLRICH JE: Expression of constitutively active cGMP-dependent protein kinase prevents glucose stimulation of thrombospondin 1 expression and TGF-beta activity. Diabetes 52:2144-2150, 2003
34. ATKINS RC: Macrophages in renal injury. Am J Kidney Dis 31:xlv-xlvii, 1998
35. RUPPRECHT HD, AKAGI Y, KEIL A, HOFER G: Nitric oxide inhibits growth of glomerular mesangial cells: Role of the transcription factor EGR-1. Kidney Int 57:70-82, 2000
36. ABDELAZIZ N, COLOMBO F, MERCIER I, CALDERONE A: Nitric oxide attenuates the expression of transforming growth factor-beta(3) mRNA in rat cardiac fibroblasts via destabilization. Hypertension 38:261-266, 2001